Impact of daily bathing with chlorhexidine gluconate on ventilator associated pneumonia in intensive care units: a meta-analysis

Wensen Chen^{1*}, Quan Cao^{2*}, Songqin Li¹, Huifen Li¹, Weihong Zhang¹

¹Department of Infection Management Office, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; ²Department of Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

*These authors contributed equally to this work.

Correspondence to: Dr. Weihong Zhang. Director of Infection Management Office, the First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Rd, Nanjing 210029, China. Email: metrischen@126.com.

Objective: Ventilator associated pneumonia (VAP) is the most important nosocomial infection in intensive care units (ICUs). Our objective was to assess whether daily bathing with chlorhexidine gluconate (CHG) would significantly result in the reduction of VAP.

Materials and methods: Meta-analysis of randomized controlled trials (RCTs) and quasi-experimental studies were conducted. The setting are medical, surgical, trauma, and combined medical-surgical ICUs. The patients are adult. We searched electronic search engine (PubMed), Embase and the Cochrane Central Register database for all published studies related to the application of daily CHG bathing with VAP risk.

Results: In all, six articles reporting a total of 27,638 ventilator-days met the inclusion criteria; 132 patients in the CHG arm developed a VAP (13,349 ventilator-days), compared with 188 patients in the control arm (14,289 ventilator-days). Daily bathing with CHG was significantly associated with decreased incidence risk of VAP [relative risk (RR): 0.73, 95% confidence interval (CI): 0.57-0.92, I²=0%]. In the subgroup analysis, we found that daily bathing with 2% CHG impregnated cloths or wipes would reduce the incidence risk of VAP among before-and-after studies (pooled RR: 0.73, 95% CI: 0.57-0.93).

Conclusions: The application of daily bathing with CHG would decrease incidence risk of VAP, which would be an important complementary intervention to barrier precautions.

Keywords: Chlorhexidine; ventilator associated pneumonia (VAP); relative risk (RR)

Submitted Dec 29, 2014. Accepted for publication Mar 26, 2015. doi: 10.3978/j.issn.2072-1439.2015.04.21 View this article at: http://dx.doi.org/10.3978/j.issn.2072-1439.2015.04.21

Introduction

Ventilator associated pneumonia (VAP) represents one of the most important nosocomial infections in critical ill patients with increased longer duration of mechanical ventilation, greater number of intensive care unit (ICU) days, hospital costs, and higher mortality (1,2). Pooled VAP density in adult ICUs in developing countries was 22.9 per 1,000 ventilator-days, at least four times as high as densities reported from the developed countries (3).

"Bundles" are a set of processes of care have been taken to

prevent morbidity of VAP (4), such as semi-recumbent body position (5), hand hygiene, daily sedation vacations (6,7), oral care with chlorhexidine gluconate (CHG) (8,9) and so on. CHG is a classic broad-spectrum antimicrobial activity with a good safety profile against gram-positive and gram-negative bacteria and safety profile (10,11). Recently, there has been a renewed interest in this antiseptic as a crucially complementary measure to prevent acquired central line associated bloodstream infection (CLABSI), surgical site infection (SSI) and antimicrobial-resistant bacteria (12,13) among critical ill patients, suggesting its robust

Journal of Thoracic Disease, Vol 7, No 4 April 2015

effects of reducing global but not specific infection rates. Interestingly, Martínez-Reséndez *et al.* revealed the potential role in preventing VAP (14). However, the results remain conflicting rather than conclusive (12,15). Therefore, this meta-analysis was performed to investigate the association between daily bathing with CHG and incidence of VAP.

Materials and methods

The whole procedures of this meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement guidelines (16).

Search strategy

An electronic search engine (PubMed), Embase and the Cochrane Central Register database were searched separately up to June 1 2014, for all eligible studies by two different reviewers (W Chen and H Li). An electronic search was performed using the following terms: "chlorhexidine", "Ventilator associated pneumonia", "VAP", "chlorhexidine bath*", "chlorhexidine washcloth*". Additional studies were identified by a hand search of references of original studies or review articles on this topic. No language restrictions were imposed. The three independent investigators (W Chen, Q Cao and W Zhang) reached consistency on all data sets for this manuscript.

Eligibility criteria

All clinical randomized controlled trials (RCTs), quasiexperimental studies that investigated the efficacy of daily using CHG bathing to prevent the morbidity of VAP among critical ill adult patients in ICU settings were eligible in this study. Studies which have been published in full-articles, and reported the number of intervention and control were included in the latter analysis. CHG bathing which was not applied as the primary part of intervention was excluded (17,18).

Data extraction

Both authors (S Li and H Li) extracted the data independently using a data extraction form. Disagreement was settled by consensus between all authors. Information on study design, setting, study population, nature of interventions, co-interventions was collected.

Quality assessment

A key feature of the Grades of Recommendations Assessment Development and Evaluation (GRADE) method developed by the Cochrane review group was used to assess the quality rather than individual study (19,20). Four categories of quality ratings in GRADE—"high", "moderate", "low" and "very low" on the representativeness of risks of bias, inconsistency, indirectness, imprecision and publication bias (*Table 1*) (23). Two authors (W Chen and S Li) assessed the quality of evidence independently following GRADE guidance (19). Disagreement between authors was resolved by discussion and finally judged by the third reviewer (W Zhang).

Statistical analysis

If the between-study heterogeneity was found, a randomeffect model was conducted. If I^2 was \leq 50%, a fixed effects model was used to calculate a pooled estimate of effect; if the I^2 statistic was >50%, a random effect model was used (15). Publication bias was evaluated by the linear regression asymmetry test by Egger *et al.* (24). All data were analyzed in Review Manager (v.5.1.6; Oxford, England) and STATA11.0 (Stata-Corp, College Station, Tex).

Results

Figure 1 summarizes the diagram of selection process. From an initial 180 potentially relevant articles, we included six in our final analysis with two RCTs and four quasiexperimental studies (*Figure 1*).

Table 1 shows the methodological quality of included trials following the GRADE method (*Table 1*). All of these available studies were conducted in ICU settings (intervention/control: 13,349 ventilator days/14,289 ventilator days) (14,23-27) (*Table 2*).

We found that daily bathing with CHG would decreased 27% risk of VAP in ICU settings [relative risk (RR): 0.73, 95% confidence interval (CI): 0.59-0.92, $I^2=0\%$] (*Figure 2*). *Figure 2* and *Table 3* summarize the subgroup analysis in this review. We found that daily bathing with CHG would lower incidence risk of VAP especially in subgroup of 2% CHG impregnated cloths or wipes (14,22,25-27) (RR: 0.73, 95% CI: 0.57-0.93) and before-and-after studies (14,25-27) (RR: 0.70, 95% CI: 0.54-0.90) (*Table 3*). Meanwhile, daily bathing with CHG may also decrease the incidence risk of VAP for two RCT studies, although no significant

Table 1	Quality of the e	vidence for	Table 1 Quality of the evidence for daily bathing with CHG for preventing VAP	h CHG for pre	venting VAP							
			Quality assessment	essment			No. of patients	atients		Effect		
No. of studies	Design	Risk of bias	Inconsistency Indirectness Imprecision	Indirectness	Imprecision	Other considerations	Intervention Control		RR (95% CI)	Absolute	Quality	Quality Importance
4	Observational No studies seri	l No serious risk of	No No serious No serious serious inconsistency indirectness risk of		No serious imprecision	No serious Reduced effect imprecision for RR >>1 or RR <<1 ¹	92/8,792 (1%)	145/10,253 RR 0.70 (1.4%) (0.54-0.90	RR 0.70 (0.54-0.90)	RR 0.70 4 fewer per 1,000 Moderate (0.54-0.90) (from 1 fewer to 7 fewer)	Moderate	Critical
		bias						1.6%		5 fewer per 1,000 (from 2 fewer to 7 fewer)		
0	Randomized Serious ² No serious trials	Serious ²	No serious inconsistency	Serious ³	No serious None imprecision	None	40/4,557 (0.9%)	43/4,036 (1.1%)	RR 0.85 (0.55-1.31)	RR 0.85 2 fewer per 1,000 (0.55-1.31) (from 5 fewer to 3 more)	Low	Critical
								1.1%		2 fewer per 1,000 (from 5 fewer to 3 more)		
¹ , Lacki study s associa	ng of standardi elected "SDD + ted pneumonia;	zation in il - daily CH(; RR, relati	¹ , Lacking of standardization in intervention protocol study selected "SDD + daily CHG bathing" as interv associated pneumonia; RR, relative risk; Cl, confidenc	col would be a tervention (21) lence interval;	a plausible co whereas the c SDD, selective	¹ , Lacking of standardization in intervention protocol would be a plausible confounding related to the effect; ² , just one RCT study used allocation concealment (21); ³ , one RCT study selected "SDD + daily CHG bathing" as intervention (21) whereas the other RCT study just chose "daily CHG bathing" (22). CHG, chlorhexidine gluconate; VAP, ventilator associated pneumonia; RR, relative risk; CI, confidence interval; SDD, selective digestive decontamination.	to the effect; ² . Ist chose "daily imination.	, just one RC y CHG bathir	T study used ng" (22). CHG	allocation conceal, chlorhexidine glu	lment (21); conate; VA	³ , one RCT P, ventilator

748

Journal of Thoracic Disease, Vol 7, No 4 April 2015




Figure 1 Flow chart of the study selection process: adapted with permission from the PRISMA flow diagram. CHG, chlorhexidine gluconate; VAP, ventilator associated pneumonia; ICU, intensive care unit.

Reference	Publication year	Study design	Setting	CHG intervention	Co-interventions or control group	Duration (months)
Camus <i>et al.</i> (21)	2005	RCT	MICU	Nasal mupirocin with 4% CHG body wash daily	Only placebo	30
Bleasdale <i>et al.</i> (22)	2007	Two-arm cross-over trial	MICU	Daily 2% CHG body wash daily with impregnated cloths	Soap and water bathing	12
Popovich <i>et al.</i> (25)	2009	Before-and- after study	MICU	Daily bath with 2% CHG washcloths	Soap and water bathing	24
Popovich <i>et al.</i> (26)	2010	Before-and- after study	SICU	Daily bath with 2% CHG washcloths	Soap and water bathing	24
Evans <i>et al.</i> (27)	2010	Before-and- after study	TICU	Daily bath with 2% CHG washcloths	Disposable washcloths without CHG	12
Martínez- Reséndez <i>et al.</i> (14)	2014	Before-and- after study	MICU and SICU	Daily with 2% CHG- impregnated wipes and hair washed with no-rinse 0.12% CHG foam shampoo	Soap and water bathing	18

CHG, chlorhexidine gluconate; RCT, randomized controlled trial; MICU, medical intensive care unit; SICU, surgical intensive care unit; TICU, trauma intensive care unit.

association was found (21,22) (RR: 0.85, 95% CI: 0.55-1.31) and longer study duration (>20 months) (21,25,26) (RR: 0.80, 95% CI: 0.57-1.11) (*Table 3*).

A sensitivity analysis by omitting individual study was performed in this meta-analysis to assess the impact of each individual study on the pooled RRs. We found the pooled RRs would not be significantly affected by omitting one multiple-center, placebo-controlled, randomized, doubleblind study (21) (RR: 0.73, 95% CI: 0.57-0.93). However, one quasi-experimental study played an important role in the pooled RRs (*Figure 3*) (remained RR: 0.81, 95% CI: 0.63-1.05) (14).

The funnel plot is used to investigate the publication bias for VAP. In our meta-analysis the funnel is asymmetric, suggesting existed publication bias (*Figure 4*).

Discussion

The impact of daily bathing with CHG to prevent healthcare associated infection (HAI), such as CLABSI (17),

	Experim	ental	Cont	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
2.3.1 CHG Bathing							
Camus, 2005	22	1849	28	1830	15.5%	0.78 [0.45, 1.35]	
Subtotal (95% CI)		1849		1830	15.5%	0.78 [0.45, 1.35]	•
Total events	22		28				
Heterogeneity: Not applicabl	le						
Test for overall effect: Z = 0.8	39 (P = 0.3	7)					
2.3.2 CHG Imprignated Cloth	h						
Martínez-Reséndez, 2014	25	2806	46	2633	26.1%	0.51 [0.31, 0.83]	
Popovich,2010	24	2452	48	3518	21.7%	0.72 [0.44, 1.17]	
Evans,2010	33	1953	38	1759	22.0%	0.78 [0.49, 1.24]	
Bleasdale, 2007	18	2708	15	2206	9.1%	0.98 [0.49, 1.94]	
Popovich,2009	10	1581	13	2343	5.8%	1.14 [0.50, 2.59]	
Subtotal (95% CI)		11500		12459	84.5%	0.73 [0.57, 0.93]	•
Total events	110		160				
Heterogeneity: Chi ² = 4.03, d	lf = 4 (P =	0.40); l ^z	= 1%				
Test for overall effect: Z = 2.5	58 (P = 0.0	10)					
Total (95% CI)		13349		14289	100.0%	0.73 [0.59, 0.92]	•
Total events	132		188				
Heterogeneity: Chi ² = 4.07, d	lf = 5 (P =	0.54); I ^z	= 0%				
Test for overall effect: Z = 2.7	'2 (P = 0.0	107)					Favours experimental Favours control
Test for subaroup difference	s: Chi² = I	0.05. df:	= 1 <i>(</i> P = 0	.83). I ² =	0%		ravours experimental ravours control

Figure 2 Risk of VAP with CHG bathing and comparator, using ventilator-days in the analysis. VAP, ventilator associated pneumonia; CHG, chlorhexidine gluconate.

	_	lr	ntervention		Control	
Measurement	No. of study	Events	Total ventilator days	Events	Total ventilator days	RR (95% CI) ^a
		(N=132)	(N=13,349)	(N=188)	(N=14,289)	
Study design						
Before-and-after study	4	92	8,792	145	10,253	0.70 (0.54-0.90
RCT	2	40	4,557	43	4,036	0.85 (0.55-1.31
CHG concentration						
2% impregnated cloths or wipes	5	110	11,500	160	12,459	0.73 (0.57-0.93
4% liquid	1	22	1,849	28	1,830	0.78 (0.45-1.35
Study settings						
MICU	3	50	6,138	56	6,379	0.91 (0.62-1.33
Others	3	82	7,211	132	7,910	0.66 (0.50-0.87
Duration of study (months) ^b						
>20	3	56	5,882	89	7,691	0.80 (0.57-1.11
≤0	3	76	7,467	99	6,598	0.69 (0.51-0.93

^a, fixed model; ^o, mean of study duration; α=0.05. CHG, chlorhexidine gluconate; VAP, ventilator associated pneumonia; RR, relative risk; CI, confidence interval; RCT, randomized controlled trial; MICU, medical intensive care unit.

SSI (15), multi-drug resistant organisms (MDROs) acquisition (12) and so on, has been well investigated in some clinical trials. However, there were limited studies to explore the association between daily bathing with CHG and incidence risk of VAP among critical ill patients undergoing mechanical ventilation. In this meta-analysis, we reviewed the published epidemiological reports on the role of daily CHG bathing which would low the incidence risk of VAP (RR: 0.73, 95% CI: 0.59-0.92). Meanwhile, we found that daily bathing with 2% CHG impregnated cloth or wipes would also decrease VAP risk among critical ill patients (RR: 0.73, 95% CI: 0.57-0.93). Our findings suggest that daily bathing with CHG would reduce the risk of VAP in ICU settings.




Figure 3 Sensitivity analysis of the association between daily bathing with CHG and VAP. CHG, chlorhexidine gluconate; VAP, ventilator associated pneumonia; CI, confidence interval.




Figure 4 Funnel plot for publication bias of the association between daily bathing with CHG and risk of VAP. CHG, chlorhexidine gluconate; VAP, ventilator associated pneumonia; RR, relative risk.

The precise mechanism to explain the association between daily bathing with CHG and VAP reduction remains unknown. In 2005, Vernon *et al.* (28) performed a prospective single-arm clinical trial in a medical ICU. A total of 1,787 patients were bathed or cleansed and assessed for acquisition of Vancomycin-Resistant Enterococcus (VRE). They found that cleansing patients with chlorhexidine saturated cloths significantly lowed VRE contamination of patients' skin, the environment (RR: 0.3, 95% CI: 0.2-0.5) and health care workers' hands (RR: 0.6, 95% CI: 0.4-0.8) and to decrease patient acquisition of VRE (RR: 0.3, 95% CI: 0.2-0.5) (28), suggesting the great role of daily CHG bathing in decreasing the "colonization pressure" which was a momentous risk factor for HAIs (29), and in reducing the risk of subsequent infection from manipulation of devices associated with the patient (14), interrupting the cross-infection in ICU settings. Above evidences may account for the potential role of daily CHG bathing in preventing the morbidity of VAP to some extent, which was consistent with the findings of our meta-analysis.

However, some important concerns merit more consideration and caution. First of all, the overall effect was more significant in before-and-after studies compared with the pooled effect from two RCT studies (Table 3). Moreover, one well designed RCT did significantly affect the pooled RRs (21), though the pooled RR would be affected by another quasi-experimental study (14) in sensitivity analysis. Our findings suggested that further well-designed studies should be performed to clarify the benefit of daily bathing with CHG for preventing VAP. In this review, GRADE method was also applied to assess the quality of this study. The benefit between the daily bathing with CHG and acquired VAP was found in observational studies and no significant heterogeneity was tested, the quality of evidence was rated "moderate" according to the GRADE system (Table 1). Two eligible RCT studies (21,22) were pooled in this meta-analysis, and we found that daily bathing with CHG might be associated with lower risk of VAP (RR: 0.85, 95% CI: 0.55-1.31), though the test for overall effect was not significant (Z=0.73, P=0.46). Recently, although daily bathing with CHG shown some benefits in preventing nosocomial infections regardless of CHG bathing is done using CHG impregnated cloths or a liquid preparation, the standard intervention protocol was still not established. In additional, conceal allocation was not available in one RCT (22). Eventually, we degraded the quality of the evidence and rated "low" according to the GRADE system (Table 1). Nevertheless, the crucial impact of the daily bathing with CHG in preventing VAP should not be neglected by infection preventionists (IPs) or healthcare workers (HCWs).

In conclusion, existing data—even if mainly obtained from quasi-experimental studies—support the practice of daily bathing with CHG for reducing VAP for critical ill patients. Additional well-designed large studies were required for the validation of this association.

Acknowledgements

Funding: This study was supported by grants from Jiangsu Province Projects of Preventive Medicine Research (Y2013044) and the Priority Academic Program

Chen et al. Daily bathing with CHG and VAP risk in ICUs

Development of Jiangsu Higher Education Institutions (PAPD) and JX10231801.

Disclosure: The authors declare no conflict of interest.

References

- 1. Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 2011;11:30-8.
- 2. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-9.
- Allegranzi B, Bagheri Nejad S, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet 2011;377:228-41.
- 4. Nolan T, Berwick DM. All-or-none measurement raises the bar on performance. JAMA 2006:295:1168-70.
- IHI. Implement the IHI Ventilator Bundle. Available online: http://www.ihi.org/knowledge/Pages/Changes/ ImplementtheVentilatorBundle.aspx
- Kress JP, Pohlman AS, O'Connor MF, et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000:342:1471-7.
- Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 2008;371:126-34.
- Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013;368:533-42.
- Chan EY, Ruest A, Meade MO, et al. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis. BMJ 2007;334:889.
- 10. Milstone AM, Passaretti CL, Perl TM. Chlorhexidine: expanding the armamentarium for infection control and prevention. Clin Infect Dis 2008;46:274-81.
- Rosenberg A, Alatary SD, Peterson AF. Safety and efficacy of the antiseptic chlorhexidine gluconate. Surg Gynecol Obstet 1976;143:789-92.
- Derde LP, Dautzenberg MJ, Bonten MJ. Chlorhexidine body washing to control antimicrobial-resistant bacteria in intensive care units: a systematic review. Intensive Care Med 2012;38:931-9.

- Chen W, Li S, Li L, et al. Effects of daily bathing with chlorhexidine and acquired infection of methicillinresistant Staphylococcus aureus and vancomycin-resistant Enterococcus: a meta-analysis. J Thorac Dis 2013;5:518-24.
- 14. Martínez-Reséndez MF, Garza-González E, Mendoza-Olazaran S, et al. Impact of daily chlorhexidine baths and hand hygiene compliance on nosocomial infection rates in critically ill patients. Am J Infect Control 2014;42:713-7.
- 15. Karki S, Cheng AC. Impact of non-rinse skin cleansing with chlorhexidine gluconate on prevention of healthcareassociated infections and colonization with multi-resistant organisms: a systematic review. J Hosp Infect 2012;82:71-84.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
- O'Horo JC, Silva GL, Munoz-Price LS, et al. The efficacy of daily bathing with chlorhexidine for reducing healthcare-associated bloodstream infections: a metaanalysis. Infect Control Hosp Epidemiol 2012;33:257-67.
- Fraser TG, Fatica C, Scarpelli M, et al. Decrease in Staphylococcus aureus colonization and hospital-acquired infection in a medical intensive care unit after institution of an active surveillance and decolonization program. Infect Control Hosp Epidemiol 2010;31:779-83.
- Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.
- 20. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
- Camus C, Bellissant E, Sebille V, et al. Prevention of acquired infections in intubated patients with the combination of two decontamination regimens. Crit Care Med 2005;33:307-14.
- 22. Bleasdale SC, Trick WE, Gonzalez IM, et al. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007;167:2073-9.
- Warren-Gash C, Fragaszy E, Hayward AC. Hand hygiene to reduce community transmission of influenza and acute respiratory tract infection: a systematic review. Influenza Other Respir Viruses 2013;7:738-49.
- Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
- 25. Popovich KJ, Hota B, Hayes R, et al. Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit.

Journal of Thoracic Disease, Vol 7, No 4 April 2015

Infect Control Hosp Epidemiol 2009;30:959-63.

- 26. Popovich KJ, Hota B, Hayes R, et al. Daily skin cleansing with chlorhexidine did not reduce the rate of central-line associated bloodstream infection in a surgical intensive care unit. Intensive Care Med 2010;36:854-8.
- 27. Evans HL, Dellit TH, Chan J, et al. Effect of chlorhexidine whole-body bathing on hospital-acquired infections among trauma patients. Arch Surg 2010;145:240-6.
- 28. Vernon MO, Hayden MK, Trick WE, et al. Chlorhexidine

Cite this article as: Chen W, Cao Q, Li S, Li H, Zhang W. Impact of daily bathing with chlorhexidine gluconate on ventilator associated pneumonia in intensive care units: a meta-analysis. J Thorac Dis 2015;7(4):746-753. doi: 10.3978/ j.issn.2072-1439.2015.04.21 gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 2006;166:306-12.

29. Bonten MJ, Slaughter S, Ambergen AW, et al. The role of "colonization pressure" in the spread of vancomycinresistant enterococci: an important infection control variable. Arch Intern Med 1998;158:1127-32.